Get started
Author

Suresh Bobba

ORCID: 0000-0002-8003-0634
Observed ORCID: 0000-0002-8003-0634
OpenAlex ID: A5041302908
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2022 · Kristie A. Blum, Jeffrey G. Supko, et al. · Cancer Research Communications · 45
PDF
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
2021 · Marina Kremyanskaya, John Mascarenhas, et al. · Blood · 22
MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
2020 · John Mascarenhas, Claire Harrison, et al. · Blood · 21
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
2024 · Jennifer Lachey, Christopher Rovaldi, et al. · Blood Advances · 17
PDF
Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.
2021 · Nehal J. Lakhani, Martin Gutierrez, et al. · Journal of Clinical Oncology · 16
Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
2024 · Claire Harrison, Lynette C.Y. Chee, et al. · Blood · 12
Durable Clinical Benefit with Ker-050 Treatment: Findings from an Ongoing Phase 2 Study in Participants with Lower-Risk MDS
2023 · Maria Diez-Campelo, David M. Ross, et al. · Blood · 11
Modulation of TGF-β Superfamily Signaling By Ker-050 Demonstrated Potential to Treat Myelofibrosis and Mitigate Ruxolitinib-Associated Cytopenia
2023 · Claire N Harrison, David M. Ross, et al. · Blood · 6
MPN-336: MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naïve Myelofibrosis Patients
2021 · John Mascarenhas, Claire Harrison, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)
2024 · Rami S. Komrokji, Maria Diez-Campelo, et al. · Blood · 3
PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study
2021 · Kristie A. Blum, Jeffrey G. Supko, et al. · Blood · 3
MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
2021 · Vikas Gupta, Marina Kremyanskaya, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
2024 · Shuhying Tan, Montserrat Arnan, et al. · Blood · 1
PDF
Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
2024 · Aristoteles Giagounidis, Monteserrat Arnan, et al. · Blood · 1
PDF
S166: Ker-050 Treatment Improved Markers of Erythropoietic Activity and Hematopoiesis Over Six Months Which Resulted in Hematological Responses Across a Broad, Lower-risk Mds Population
2023 · Aristoteles Giagounidis, Thomas Cluzeau, et al. · HemaSphere · 1
Ker-050 Treatment Reduced Iron Overload and Increased Bone Specific Alkaline Phosphatase in Participants with Lower-Risk MDS Supporting Potential to Restore Balance to the Osteohematopoietic Niche
2023 · Lynette C.Y. Chee, David M. Ross, et al. · Blood
PDF
Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S3 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Supplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S1 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S2 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S3 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Figure S1 from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023 · Kristie A. Blum, Jeffrey G. Supko, et al.
Works count: 27
Citation count: 167
H-index: 7
I10-index: 7
Year
Topic
Type